In Germany, the BioNTech-Pfizer vaccine is recommended for children over 12 years of age with certain diseases

class = “cf”>

According to the statement made by the Robert Koch Institute, the Standing Committee on Immunization (STIKO) recommended that young people and children with certain diseases receive the BioNTech-Pfizer vaccine due to the possibility of severe transmission of Kovid- 19.

In the statement, it was stated that the vaccine is generally not recommended for children and youth between the ages of 12 and 17 who have no disease at the moment, but it was noted that the vaccine can also be applied to this group on demand. of the child and the parent after doctor’s recommendation.

The specific diseases in question include obesity, various heart diseases, chronic lung and kidney disease, Down syndrome and diabetes, the statement said.

In a statement to the German News Agency (DPA), STIKO Chairman Thomas Mertens said it was necessary to weigh the possible benefits and risks when making this decision, and said the risk of getting seriously ill with Kovid-19 is low for 12 -17 years.

Mertens shared the information that only 2 deaths occurred in this age group in Germany and said both people had severe pre-illness.
The European Union’s medicines regulatory agency, the European Medicines Agency (EMA), has approved the BioNTech-Pfizer vaccine to be administered to the 12-15 age group at the end of May.

class = “cf”>


In addition, the US pharmaceutical company Moderna has asked the US Food and Drug Administration (FDA) for the use of a new type of vaccine against the coronavirus (Kovid-19) in children.

In the written statement made on the company’s website, it was stated that the necessary documents had been submitted to the federal institution for the emergency use of the Kovid-19 vaccine in children aged 12 to 17 years. .

The Moderna vaccine, which is the second vaccine approved by the FDA after the Pfizer / BioNTech Kovid-19 vaccine in the country, can be given to adults 18 years of age and older.

In a statement by Moderna on May 25, it was stated that the vaccine under study against Kovid-19 provides full protection for children between the ages of 12 and 17.

In the statement, it was stated that 3,000,732 people had received a vaccine and a placebo in clinical trials, and the vaccine was reported to trigger symptoms of immune protection in young people in the mentioned age group. , as in adults, and on the other hand, it caused temporary side effects such as numbness in the arm and headache.

On May 10, the FDA approved the Kovid-19 vaccine produced by the US company Pfizer and the German biotech company BioNTech for use in children aged 12 to 15 years.

Bigpara for cryptocurrency markets

Bigpara for cryptocurrency markets

Add a Comment